FLSM
CERE

Frazier Life Sciences Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Frazier Life Sciences Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-393,000
Closed -$16.1M – 57
2024
Q2 		$16.1M Hold
393,000
– – 0.75% 30
2024
Q1 		$16.6M Hold
393,000
– – 0.7% 33
2023
Q4 		$16.7M Hold
393,000
– – 0.89% 30
2023
Q3 		$8.58M Hold
393,000
– – 0.57% 34
2023
Q2 		$12.5M Hold
393,000
– – 0.75% 30
2023
Q1 		$9.59M Hold
393,000
– – 0.69% 30
2022
Q4 		$12.4M Hold
393,000
– – 0.77% 26
2022
Q3 		$11.1M Buy
393,000
+190,740
+94% +$5.68M 0.86% 28
2022
Q2 		$5.35M Buy
202,260
+146,425
+262% +$4.16M 0.5% 32
2022
Q1 		$1.96M Buy
+55,835
New +$1.63M 0.17% 40

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Frazier Life Sciences Management's CERE Position: Q3 2024 in Review

Frazier Life Sciences Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 393,000 shares — an estimated $16.1M sold.

Frazier Life Sciences Management first reported a position in CERE in Q1 2022 and held it in 10 quarters. The position peaked at $16.7M in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Frazier Life Sciences Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Frazier Life Sciences Management sold 393,000 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $16.1M.
  • Frazier Life Sciences Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2022 and held it in 10 quarters.
  • Frazier Life Sciences Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $16.7M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Frazier Life Sciences Management's 13F filing for Q3 2024, filed 15 Nov 2024.